Artemisinin-based therapies, derived from the sweet wormwood plant, transformed malaria treatment around the year 2000 just as older drugs were failing because the parasite had evolved resistance. Medicines for Malaria Venture researcher George Jagoe notes the large death toll of the late 1990s and early 2000s—about 2 million per year—was driven by drug failure, and that no one wants a repeat of that crisis.
Those drugs have since saved millions and remain the global standard, but signs of artemisinin resistance have emerged, first in Southeast Asia and now in parts of Africa. That trend has increased demand for new treatments that attack the parasite by different mechanisms.
After more than two decades of work, a promising alternative is nearing readiness. GanLum, a fixed-dose combination of a novel compound called ganaplacide with the older partner lumefantrine, showed over 97% efficacy in clinical trials run in 12 African countries, according to investigators who presented the findings at a recent tropical medicine meeting. Kasturi Haldar, a veteran malaria researcher, described the advance as important and timely.
Novartis discovered ganaplacide after screening more than 2.3 million molecules. Laboratory studies indicate it interferes with the parasite’s ability to survive inside human red blood cells, is active against all known parasite forms including strains carrying mutations associated with artemisinin resistance, and targets the stage that enables transmission to mosquitoes. Blocking transmission as well as clearing infection is an advantage because it can slow the spread of resistant parasites.
The clinical program enrolled more than 16,000 people aged two and older with malaria across a dozen African countries. Participants were randomized: half received GanLum over three days, and half received the current artemisinin-based standard of care. Both regimens performed similarly overall, with GanLum slightly ahead in efficacy. Side effects were comparable between groups—nausea and diarrhea were common in both—but vomiting occurred more often among GanLum recipients.
Independent experts say a new drug like GanLum could become an important tool if artemisinin-based treatments begin to fail more widely. David Fidock of Columbia University points out that partial artemisinin resistance is spreading in parts of Africa and that alternatives will be necessary should resistance translate into clinical treatment failure.
GanLum must still clear additional regulatory steps before it can be widely used; the study team estimates roughly a year and a half for the next regulatory milestones. Even if approved, GanLum is unlikely to replace artemisinin combinations immediately everywhere, since those drugs remain effective in many locations. Instead, GanLum could be deployed in areas where artemisinin efficacy is compromised, helping to preserve the usefulness of both options and to avoid the surge in deaths seen when resistance overwhelms available treatments.